NCT01767311: A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer's Disease
- State
- Completed
- Phase
- Phase 2
- People
- 856 taking part
- Started
- 20 Dec 2012
- Primary completion
- 10 Dec 2024
- Arms
- Core Study: Lecanemab 2.5 mg/kg biweekly, Core Study: Lecanemab 5.0 mg/kg biweekly, Core Study: Lecanemab 10 mg/kg biweekly, Core Study: Lecanemab 5.0 mg/kg monthly, Core Study: Lecanemab 10 mg/kg monthly, Extension Phase: Lecanemab 10 mg/kg
- Results
- Posted on the registry
- 20 Dec 2012: Trial started
- 14 Jan 2013: Trial registered
- 10 Dec 2024: Trial completed
- 4 Mar 2026: Trial results posted